🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Javier Cortés

Universitat de Girona

ORCID: 0000-0001-7623-1583

Also affiliated with Boiron (France), Villa Maria Hospital, Hospital Universitario de Torrejón, MedSIR (Spain), International Breast Cancer Study Group, Vall d'Hebron Institute of Oncology, Universidad Europea de Madrid

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

3in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 3 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 10 papers. Top paper: “A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation”.

A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation

The Lancet Oncology(2020)10.1016/s1470-2045(20)30450-2

N/A

0.650DataRank · unranked

75 citations

Valentina Guarneri, Laia Paré, Gaia Griguolo, Tomás Pascual, Maria Vittoria Dieci +34 more

Analysis of tumor infiltrating CD4+ and CD8+ CDR3 sequences reveals shared features putatively associated to the anti-tumor immune response

Frontiers in Immunology(2023)10.3389/fimmu.2023.1227766

N/A

0.476DataRank · unranked

9 citations

Gonzalo Lázaro, Vicente Marco, Elisa Molina, Ferran Abancó, Vicente Peg +6 more

Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network—Breast dataset (SCAN-B)

ESMO Open(2024)10.1016/j.esmoop.2024.102388

N/A

0.442DataRank · unranked

18 citations

Tomás Pascual, Fara Brasó‐Maristany, Laia Paré, Olga Martínez‐Sáez, Javier Cortés +15 more

Randomized Phase III Study of Amcenestrant Plus Palbociclib Versus Letrozole Plus Palbociclib in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Primary Results From AMEERA-5

Journal of Clinical Oncology(2024)10.1200/jco.23.02036

N/A

0.434DataRank · unranked

17 citations

Sara A. Hurvitz, Joyce O'Shaughnessy, Suzette Delaloge, Hiroji Iwata, Hope S. Rugo +11 more

Moving toward response-adapted trials in oncology

Nature Medicine(2024)10.1038/s41591-024-03346-3

N/A

0.165DataRank · unranked

2 citations

Gabriele Antonarelli, Maria Gion, Antonio Llombart-Cussac, Javier Cortés, Jose Pérez-García

Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2-positive early breast cancer (EBC)

Annals of Oncology(2024)10.1016/j.annonc.2024.12.010

N/A

0DataRank · unranked

3 citations

Maki Tanioka, Sung Gwe Ahn, Paola Zagami, Tomás Pascual, Mattia Rediti +18 more

Systemic treatment of immune checkpoint inhibitor‐induced psoriasis: Inference‐based guidance

Journal of the European Academy of Dermatology and Venereology(2025)10.1111/jdv.20809

N/A

0DataRank · unranked

10 citations

L. Puig, Jennifer Beecker, Vinod Chandran, Joël Claveau, Javier Cortés +10 more

Surrogate endpoints for overall survival in randomized clinical trials testing immune checkpoint inhibitors: a systematic review and meta-analysis

Frontiers in Immunology(2024)10.3389/fimmu.2024.1340979

N/A

0DataRank · unranked

4 citations

Eleonora Pagan, Laura Pala, Chiara Oriecuia, Marco Musca, Claudia Specchia +8 more

Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells

Breast Cancer Research and Treatment(2023)10.1007/s10549-023-06998-w

N/A

0DataRank · unranked

6 citations

Aditya Bardia, Brian Chirn, Brittany A. Reeves, Joseph A. LiCausi, Risa Burr +18 more

Understanding the activity of antibody–drug conjugates in primary and secondary brain tumours

Nature Reviews Clinical Oncology(2023)10.1038/s41571-023-00756-z

N/A

0DataRank · unranked

93 citations

Rupert Bartsch, Émilie Le Rhun, Anna S. Berghoff, Priscilla K. Brastianos, Javier Cortés +8 more